Tumor immune microenvironment (TIME) include tumor cells, immune cells, cytokines, etc.
The interactions between these components, which are divided into anti-tumor and pro …

Colorectal cancer is the third most common cancer in the world with increasing incidence
and mortality rates globally. Standard treatments for colorectal cancer have always been …

Background Advanced prostate cancer remains one of the most common and deadly
cancers, despite advances in treatment options. Immunotherapy has provided little benefit to …

Dendritic cells (DC) are specialized immune cells that play a critical role in promoting an
immune response against Ags, which can include foreign pathogenic Ags and self-tumor …

Tumours grow within an intricate network of epithelial cells, vascular and lymphatic vessels,
cytokines and chemokines, and infiltrating immune cells. Different types of infiltrating …

Since the mid-1990s, dendritic cells have been used in clinical trials as cellular mediators for
therapeutic vaccination of patients with cancer. Dendritic cell-based immunotherapy is safe …

Dendritic cell (DC) vaccination in cancer patients aims to induce or augment an effective
antitumor immune response against tumor antigens and was first explored in a clinical trial …

The presence of inflammatory immune cells in human tumors raises a fundamental question
in oncology: How do cancer cells avoid the destruction by immune attack? In principle, tumor …

The immunotherapy of cancer has made significant strides in the past few years due to
improved understanding of the underlying principles of tumor biology and immunology …

Dendritic cells (DCs) are a heterogeneous group of antigen-presenting innate immune cells
that regulate adaptive immunity, including against cancer. Therefore, understanding the …